Cardlytics, Inc. (NASDAQ:CDLX) Receives Consensus Rating of "Hold" from Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX - Get Free Report) have earned a consensus rating of "Hold" from the seven ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $6.92.

A number of brokerages have recently issued reports on CDLX. Evercore ISI initiated coverage on shares of Cardlytics in a research report on Friday, October 11th. They issued an "in-line" rating and a $4.00 price target on the stock. Craig Hallum raised shares of Cardlytics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 6th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Cardlytics in a research note on Friday, January 17th.

Cardlytics Trading Down 3.0 %

Shares of NASDAQ:CDLX traded down $0.10 during midday trading on Thursday, hitting $3.07. 500,544 shares of the stock were exchanged, compared to its average volume of 1,016,474. The business's 50-day moving average price is $3.65 and its 200 day moving average price is $4.27. Cardlytics has a 12 month low of $2.76 and a 12 month high of $20.52. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The stock has a market capitalization of $155.76 million, a price-to-earnings ratio of -0.50 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.18. The firm had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The company's revenue for the quarter was down 15.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.26) earnings per share. Analysts predict that Cardlytics will post -1.52 earnings per share for the current year.

Insiders Place Their Bets

In other Cardlytics news, CFO Alexis Desieno sold 8,854 shares of the company's stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $3.67, for a total transaction of $32,494.18. Following the transaction, the chief financial officer now owns 121,976 shares in the company, valued at approximately $447,651.92. This represents a 6.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amit Gupta sold 15,160 shares of the business's stock in a transaction on Friday, January 24th. The shares were sold at an average price of $3.92, for a total transaction of $59,427.20. Following the sale, the chief executive officer now owns 215,494 shares in the company, valued at approximately $844,736.48. This trade represents a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,560 shares of company stock valued at $223,687 over the last 90 days. Insiders own 4.40% of the company's stock.

Institutional Trading of Cardlytics

A number of institutional investors and hedge funds have recently bought and sold shares of CDLX. GSA Capital Partners LLP lifted its holdings in shares of Cardlytics by 1,273.2% during the third quarter. GSA Capital Partners LLP now owns 382,315 shares of the company's stock valued at $1,223,000 after purchasing an additional 354,474 shares in the last quarter. RBF Capital LLC lifted its holdings in shares of Cardlytics by 311.9% during the 3rd quarter. RBF Capital LLC now owns 488,128 shares of the company's stock valued at $1,562,000 after buying an additional 369,620 shares during the period. Geode Capital Management LLC grew its holdings in shares of Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company's stock worth $3,371,000 after acquiring an additional 73,484 shares during the period. Barclays PLC lifted its stake in shares of Cardlytics by 223.9% in the 3rd quarter. Barclays PLC now owns 58,026 shares of the company's stock worth $186,000 after purchasing an additional 40,112 shares during the period. Finally, SG Americas Securities LLC bought a new stake in shares of Cardlytics during the 3rd quarter valued at $45,000. 68.10% of the stock is currently owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.